IPR decision: Nov. 13, 2019
|
AIA Review #
|
Filing Date
|
Institution Date
|
Petitioner
|
Patent
|
Respondent
|
FINAL WRITTEN
DECISION
|
|
IPR2018-00974
|
04/27/2018
|
11/14/2018
|
Mallinckrodt
|
9,655,945
|
BioVie, Inc.
|
All Challenged
Claims Unpatentable
|
US 9,655,945 (Biovie Inc.;
Exp: Jun 30, 2036) – Non-OB
1. A method for treating a patient diagnosed with ascites
due to liver cirrhosis, the method comprising administering terlipressin
or salt thereof as a continuous infusion dose of about 1.0 mg to about 12.0 mg
per day to the patient for about one day to about 12 months.
7. A method for reducing the accumulation of ascitic fluid in the abdominal cavity in an ambulatory ascites patient, the method comprising administering to the patient terlipressin or salt thereof as a continuous infusion dose of about 1.0 mg to about 12.0 mg per day for about one day to about twelve months with an ambulatory infusion pump.
7. A method for reducing the accumulation of ascitic fluid in the abdominal cavity in an ambulatory ascites patient, the method comprising administering to the patient terlipressin or salt thereof as a continuous infusion dose of about 1.0 mg to about 12.0 mg per day for about one day to about twelve months with an ambulatory infusion pump.
No comments:
Post a Comment